

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

\*FHK- Florida Healthy Kids

## Ninlaro (ixazomib)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Ninlaro (ixazomib)	May be subject to quantity limit

### APPROVAL CRITERIA

Requests for Ninlaro (ixazomib) may be approved if the following criteria are met:

- I. Individual has a diagnosis of Multiple myeloma; **AND**
- II. Individual has received at least one prior therapy; **AND**
- III. Ninlaro (ixazomib) is given as part of a treatment regimen containing lenalidomide and dexamethasone;  
**OR**
- IV. Ninlaro (ixazomib) is given in combination with dexamethasone (NCCN 2A);  
**OR**
- V. Individual has a diagnosis of multiple myeloma; **AND**
- VI. Individual has received at least two prior therapies, including an immunomodulatory agent and a proteasome inhibitor; **AND**
- VII. Individual has demonstrated disease progression on or within 60 days of completion of last therapy; **AND**
- VIII. Ninlaro (ixazomib) is given as part of a treatment regimen containing dexamethasone and pomalidomide (NCCN 2A).

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

\*FHK- Florida Healthy Kids

**Key References:**

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2018. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: October 2018.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.
5. The NCCN Drugs & Biologics Compendium (NCCN Compendium™) © 2018 National Comprehensive Cancer Network, Inc. Available at: NCCN.org. Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.